[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delayed-graft-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delayed-graft-function":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,68,99,122,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100579938","phase-3-double-blind-randomized-placebo-controlled-multicenter-study-to-evaluate-the-efficacy-and-safety-of-ravulizumab-administered-intravenously-in-adult-participants-at-high-risk-of-delayed-graft-function-after-kidney-transplantation-100579938",false,"NCT06830798","Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","AWAKE","Inclusion Criteria:\n\n* ≥ 18 years of age at the time of signing the informed consent\n* Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)\n* A candidate for kidney transplant from:\n\n  1. Donation after Circulatory Death (DCD) donor\n  2. High-risk Donation after Brain Death (DBD) donor\n\nExclusion Criteria:\n\n* Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification\n* Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.","ALL","18 Years",{"count":20,"type":21},450,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.",[27,28,29],"Delayed Graft Function","DGF","Kidney Transplant",[27,28,29,31],"Ravulizumab","RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":36},"2025-05-19",{"date":40,"type":21},"2028-08-30",{"name":42,"class":43},"Alexion Pharmaceuticals, Inc.","INDUSTRY",130,{"id":46,"slug":4,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100581857","NCT06855758","Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation","Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation, A Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with end-stage renal disease aged 18 years or above\n\nExclusion Criteria:\n\n* simultaneous multiple organ transplantation\n* known allergy to study medication\n* known pregnancy status\n* cancellation of surgery due to grafts or personal reasons\n* persistent severe preoperative hypertension that may not require intraoperative supportive therapy with vasoactive medications\n* any other reason that the supervising physician or the anesthesiologist on duty think the patient is not suitable for the study",{"count":52,"type":21},150,[54],"NA","Prospective double blind randomized controlled trial. By randomizing patients undergoing kidney transplantation into a conventional catecholamine drug (dobutamine) blood pressure maintenance group and a terlipressin-complexed dobutamine group, the investigators compared the effect of intraoperative blood pressure maintenance and the dosage of the vasoactive drug, postoperative graft function, delayed graft function, and other related complications between the two groups, in order to demonstrate whether the use of terlipressin for blood pressure regulation during kidney transplantation is superior to the existing treatments.",[29,27,57],"Intraoperative Hypotension","2026-06-16",{"date":33,"type":36},{"date":61,"type":36},"2025-03-06",{"date":63,"type":21},"2027-06",{"name":65,"class":66},"Beijing Friendship Hospital","OTHER",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":67},"100362920","phase-1-safety-and-efficacy-of-treprostinil-remodulin-in-reducing-ischemia-reperfusion-injury-during-kidney-transplantation-100362920","NCT04005469","Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation","A Phase I\u002FII Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation","Inclusion Criteria:\n\n1. Male and female patients who will receive a deceased donor kidney aged 18 to 65 (inclusive) and are currently on the active transplant list at RIH.\n2. Documentation of a diabetes diagnosis as evidenced by one or more clinical features consistent will be noted for all patients.\n3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. Under the age of 18 years\n2. Difficult venous access\n3. BMI \\> 40 kg\u002Fm2\n4. Patients with severe clinical gastroparesis as determined by repeated vomiting\n5. Prior GI surgery except for cholecystectomy, appendectomy, or Nissen fundoplication\n6. Known or history of inflammatory bowel disease or bezoars\n7. History of diverticulitis, diverticular stricture, and other intestinal strictures\n8. Be receiving any investigational drug other than treprostinil or participating in any other investigational study\n9. Be receiving any prostanoid therapy to treat portopulmonary hypertension\n10. Have any known hypersensitivity to prostaglandins, prostacyclin or treprostinil\n11. Have had a failed kidney transplant within the previous 180 days\n12. Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results\n13. Those with significant cardiovascular disease including treatment with inotropes\n14. If female, be pregnant or nursing (confirmed by urine test)\n15. Presence of a condition or abnormality that in the opinion of the Investigators that would compromise the safety of the patient or the quality of the data","75 Years",{"count":77,"type":21},20,[79,80],"PHASE1","PHASE2","The objectives of this study are to test the preliminary safety and efficacy of a two-day peri-operative course of treprostinil in reducing ischemia-reperfusion injury in adult patients receiving a deceased donor kidney transplantation. Treprostinil, a prostacyclin analog, is expected to facilitate the restoration of blood supply to the revascularized kidney graft via its vasodilatory actions, well characterized protective effects, and longer elimination half-life. These properties and actions of treprostinil make it a strong drug candidate to reduce kidney graft dysfunction during kidney transplantation. An anticipated 20 participants undergoing deceased donor kidney transplant will be hospitalized and intensively monitored during an entire two-day Treatment Phase. An IV infusion using a dedicated central venous line will be used to administer treprostinil commencing approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of the transplant surgery. The primary endpoints include the safety and efficacy of treprostinil, with secondary endpoints including the evaluation of both biochemical and clinical endpoints post-transplantation.",[83,27],"Ischemia Reperfusion Injury",[85,86,87,88,89],"Ischemia-reperfusion injury","kidney transplantation","prostacyclin","treprostinil","delayed graft function","2026-04-20",{"date":92,"type":36},"2026-04-23",{"date":94,"type":36},"2020-11-13",{"date":96,"type":21},"2028-06-30",{"name":98,"class":66},"Rhode Island Hospital",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100614133","phase-1-the-effects-of-vonoprazan-fumarate-on-dgf-incidence-in-dd-kidney-transplant-recipients-100614133","NCT07275632","The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients","A Multicenter, Single-Arm, Exploratory Study Evaluating the Effect of Perioperative Oral Vonoprazan Fumarate on the Incidence of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients","Inclusion Criteria:\n\n* Age ≥ 18 years at time of transplantation.\n* Undergoing first-time deceased-donor kidney transplantation.\n* No administration of proton-competitive acid blockers (P-CABs) in the 1 month prior to transplantation.\n* Consent to receive the standard immunosuppressive therapy post-transplantation.\n* Ability and willingness to provide informed consent and comply with study procedures and follow-up.\n* Complete baseline clinical data available.\n\nExclusion Criteria:\n\n* Receiving a living-donor kidney transplant or multi-organ transplantation.\n* Previous history of any solid organ or cellular transplantation (with the exception of corneal transplants).\n* Intraoperative occurrence of hyperacute rejection or confirmed graft non-function (e.g., renal artery thrombosis).\n* Presence of high risk for primary graft non-function (e.g., severe injury to the transplant renal artery).\n* Severe postoperative intestinal obstruction requiring prolonged fasting or inability to take oral medication in perioperative period.\n* Known history of hypersensitivity to vonoprazan fumarate or any of its excipients.\n* Subjects with severe hepatic impairment (Child-Pugh Class C).\n* Concomitant use of strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin).\n* Current therapy with atazanavir or rilpivirine.\n* Any other condition deemed by the investigator to be inappropriate for study participation (e.g., uncontrolled active infection, severe peptic ulcer, pregnancy or lactation).",{"count":107,"type":21},47,[79,80],"This is an exploratory, multicenter, single-arm study designed to evaluate the efficacy of perioperative Vonoprazan Fumarate in reducing the incidence of Delayed Graft Function (DGF) in deceased-donor kidney transplant recipients. DGF is a common early complication that significantly impacts graft function and long-term transplant survival. This study aims to explore how Vonoprazan Fumarate, a potassium-competitive acid blocker (P-CAB), can potentially improve macrophage phagocytic function, reduce kidney inflammation, and enhance early kidney function recovery.\n\nPatients aged 18 years and older who are undergoing first-time deceased-donor kidney transplantation will be enrolled. Vonoprazan Fumarate will be administered daily starting on the day of transplantation and continuing for seven days post-surgery. The primary endpoint is DGF incidence, while secondary endpoints include kidney function recovery, serum creatinine reduction, estimated glomerular filtration rate, and safety assessments. Adverse events will be monitored, and the study will also explore potential biomarkers for inflammation and graft function.\n\nThe study is expected to provide insights into a potential new therapeutic strategy to reduce DGF and improve early kidney transplant outcomes, potentially benefiting future kidney transplant patients by offering a safer and more effective perioperative treatment option.",[27,111],"Kidney Transplantation","2025-12-17",{"date":114,"type":36},"2025-12-23",{"date":116,"type":36},"2025-12-10",{"date":118,"type":21},"2026-12-31",{"name":120,"class":66},"First Affiliated Hospital of Chongqing Medical University",2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100544309","norepinephrine-infusion-combined-with-goal-directed-fluid-therapy-in-patients-undergoing-kidney-transplantations-100544309","NCT06367205","Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations","Norepinephrine Infusion Combined With Goal-directed Fluid Therapy Reduces Delayed Graft Function Incidence in Patients Undergoing Kidney Transplantations: a Randomized Multicenter Clinical Trial","Inclusion Criteria:\n\n1. Recipients aged 18 years or older\n2. Scheduled to undergo kidney transplantations under general anesthesia\n3. Cadaveric kidney transplantations\n4. Sign the informed consent form\n\nExclusion Criteria:\n\n1. Donors aged under 18 years\n2. Donor kidneys classified as Maastricht category I or II\n3. Contraindications to radial artery catheterization\n4. Pregnancy\n5. Cardiac dysfunction (exercise tolerance less than 4 METS)\n6. Severe liver dysfunction (Child Pugh C-grade)\n7. Respiratory diseases with tidal volume intolerance exceeding 8ml\u002Fkg\n8. Severe arrhythmias, including atrial fibrillation, frequent atrial or ventricular premature beats, moderate or severe aortic and mitral regurgitation\n9. Double-kidney transplantations\n10. Simultaneous organ or additional surgeries during kidney transplantations\n11. Repeat kidney transplantations\n12. Concurrent participation in other clinical trials\n13. Patients deemed ineligible by researchers",{"count":130,"type":21},380,[54],"Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients. The primary objective of this study is to investigate the potential efficacy of norepinephrine infusion in conjunction with goal-directed fluid therapy (GDFT) in mitigating the occurrence of DGF among individuals undergoing kidney transplantations. The findings of this investigation have the potential to advance the field of perioperative care in kidney transplantations by providing insights into optimized management strategies.",[27,134,111],"End Stage Renal Disease",[136,137,138],"Norepinephrine","Goal-directed fluid therapy","Randomized controlled trial","2024-04-15",{"date":141,"type":36},"2024-04-16",{"date":143,"type":36},"2024-03-01",{"date":145,"type":21},"2026-06-30",{"name":147,"class":66},"RenJi Hospital",3,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":67},"100291266","furosemide-stress-test-predicting-early-graft-function-in-kidney-transplantation-100291266","NCT03071536","Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation","Furosemide Stress Test as a Marker of Postoperative Kidney Allograft Function","FOSTIK","Inclusion Criteria:\n\n* Deceased donor kidney transplantation at KCMH\n* informed consent is accepted\n\nExclusion Criteria:\n\n* Known allergy to furosemide\n* Surgical complication of allograft\n* Urgently needed for dialysis (refractory hypervolemia, uremic symptoms, and hyperkalemia)","80 Years",{"count":159,"type":21},180,[54],"Furosemide is an old drug that has been used frequently in the postoperative period of kidney transplantation, aiming to achieve adequate urine output. There is no previous study that directly evaluate the urine response to standardized dose of furosemide in the postoperative period. The objective is to measure the urine output after standardized dose of furosemide is delivered, as a biomarker to predict the graft function in perioperative period.",[163,164,27],"Kidney Function","Kidney Transplant; Complications",[166,86,167,168,89],"furosemide stress test","urine output","perioperation","2024-01-15",{"date":171,"type":36},"2024-01-17",{"date":173,"type":36},"2016-11-25",{"date":175,"type":21},"2027-05",{"name":177,"class":66},"King Chulalongkorn Memorial Hospital"]